Profile data is unavailable for this security.
About the company
Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. The Company operates its businesses through three segments. The Non-clinical Drug Research Service segment mainly provides non-clinical drug safety evaluation services, pharmacodynamic research services, and pharmacokinetic research services. The Clinical Services and Others segment mainly provides pre-market clinical services and pharmacovigilance services for drugs. The Experimental Model Supply segment is responsible for the production and sales of experimental models and their ancillary products. The Company conducts its businesses both in the domestic market and overseas markets.
- Revenue in CNY (TTM)1.67bn
- Net income in CNY225.09m
- Incorporated1998
- Employees2.65k
- LocationJoinn Laboratories China Co LtdA5 Rongjing East StreetEconomic-Technological Development AreaBEIJING 100176ChinaCHN
- Phone+86 1 067869582
- Fax+86 1 067869582
- Websitehttps://www.joinnlabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InventisBio Co Ltd | 180.53m | -116.28m | 13.15bn | 185.00 | -- | 7.89 | -- | 72.82 | -0.2012 | -0.2012 | 0.3122 | 2.88 | 0.0988 | -- | 1.03 | 975,824.70 | -6.36 | -32.89 | -6.76 | -35.22 | 99.41 | -- | -64.41 | -682.73 | -- | -- | 0.0127 | -- | -9.02 | 25.00 | 15.41 | -- | -3.97 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 624.52m | -947.49m | 14.81bn | 1.36k | -- | 19.46 | -- | 23.72 | -2.37 | -2.37 | 1.56 | 1.90 | 0.1384 | 0.3458 | 14.57 | 441,048.00 | -21.06 | -29.90 | -36.19 | -36.18 | 88.72 | 85.56 | -152.14 | -1,188.68 | 0.8093 | -10.82 | 0.7353 | -- | 56.28 | 46.68 | 0.9031 | -- | 12.25 | -- |
| Sinocelltech Group Ltd | 1.89bn | -310.15m | 18.00bn | 2.28k | -- | -- | -- | 9.54 | -0.6964 | -0.6964 | 4.24 | -0.1083 | 0.5458 | 0.4325 | 3.04 | 828,989.10 | -8.37 | -22.66 | -29.60 | -48.25 | 93.51 | 95.52 | -15.33 | -42.96 | 0.5008 | -0.6753 | 1.02 | -- | 33.13 | 294.24 | 127.39 | -- | 23.95 | -- |
| BeBetter Med Inc | -100.00bn | -100.00bn | 19.80bn | 150.00 | -- | 91.93 | -- | -- | -- | -- | -- | 0.4785 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0116 | -- | -- | -- | 67.59 | -- | -- | -- |
| InnoCare Pharma Ltd | 1.43bn | -229.64m | 23.32bn | 1.15k | -- | 6.43 | -- | 16.34 | -0.1508 | -0.1508 | 0.8855 | 3.78 | 0.1504 | 1.70 | 3.74 | 1,245,225.00 | -2.52 | -6.41 | -2.87 | -7.45 | 86.97 | 86.07 | -16.78 | -71.71 | 6.44 | -- | 0.1996 | -- | 36.68 | 281.63 | 30.20 | -- | 3.42 | -- |
| Dizal Pharmaceutical Co Ltd | 607.75m | -867.44m | 25.42bn | 852.00 | -- | 17.45 | -- | 41.82 | -2.01 | -2.01 | 1.40 | 3.14 | 0.2644 | 0.8102 | 5.84 | 713,322.50 | -37.97 | -46.55 | -55.30 | -56.24 | 95.12 | 90.63 | -143.64 | -825.75 | 2.42 | -111.09 | 0.4239 | -- | 294.24 | 54.40 | 23.63 | -- | 58.33 | -- |
| Joinn Laboratories China Co Ltd | 1.67bn | 225.09m | 25.74bn | 2.65k | 108.83 | 3.42 | -- | 15.43 | 0.3405 | 0.3405 | 2.37 | 10.84 | 0.175 | 0.7843 | 6.03 | 629,011.80 | 2.36 | 6.60 | 2.72 | 7.92 | 24.63 | 41.87 | 13.47 | 25.98 | 3.06 | -- | 0.0039 | 23.59 | -15.07 | 25.85 | -81.34 | -16.89 | 16.27 | -19.46 |
| Wuhan Healthgen Biotechnology Corp | 23.39m | -160.81m | 26.43bn | 215.00 | -- | 53.18 | -- | 1,130.12 | -0.4498 | -0.4498 | 0.0654 | 1.39 | -- | -- | -- | 131,386.80 | -- | -- | -- | -- | 41.12 | -- | -687.60 | -- | 0.359 | -30.87 | 0.5497 | -- | 3.92 | -- | 19.04 | -- | -- | -- |
| Biocytogen Phrmutcls (Beijing) Co Ltd | 1.33bn | 249.94m | 30.84bn | 1.28k | 136.52 | 34.97 | 79.42 | 23.16 | 0.5593 | 0.5593 | 2.98 | 2.18 | -- | -- | -- | 1,215,939.00 | -- | -- | -- | -- | 76.56 | -- | 18.77 | -- | 1.11 | 14.77 | 0.5281 | -- | 36.76 | -- | 108.76 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Joinn Laboratories China Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
8.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hwabao WP Fund Management Co., Ltd.as of 31 Mar 2025 | 12.39m | 1.97% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 7.75m | 1.23% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 6.76m | 1.07% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 5.86m | 0.93% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 5.58m | 0.89% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 4.84m | 0.77% |
| Caitong Securities Asset Management Co., Ltd.as of 30 Jun 2025 | 3.36m | 0.53% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2025 | 2.95m | 0.47% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 2.58m | 0.41% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 1.83m | 0.29% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
